pf00562271
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00666926)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Focal adhesion kinase 1INHIBITOR
PTK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O- Mol. weight
- 507.5 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1084546 ↗
Also known as
- pf00562271
- pf00562271
- pf-00562271
- pf-00562271
- pf-562271
- pf-562271
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00666926 | Phase 1 | Dec 1, 2005 | Pfizer, Verastem, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 0 | 1 | 2005 |
| Verastem, Inc. | For profit | 1 | 1 | 1 | 2005 |
2 organizations
Page 1 / 1